V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20187251 | 20158064 | 0 | 65 | Palliative (P) | 2018-06-13 | 2018-06-13 | Bevacizumab + Olaparib | 02 | N | VINORELBINE | 101844547 |
| 20187474 | 20158065 | 1.75 | 77 | Palliative (P) | 2019-05-22 | 2019-07-15 | MIC | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100259446 |
| 20188987 | 20158068 | 1.79 | null | Adjuvant (A) | null | 2021-01-18 | CAV | N | N | CISPLATIN + FLUOROURACIL + MITOMYCIN | 101684297 |
| 20189120 | 20158069 | 1.48 | 72.8 | Adjuvant (A) | 2017-01-17 | 2017-01-26 | CAM-PLEX Trial | 02 | N | INTERAACT TRIAL | 100307706 |
| 20189383 | 20158070 | 1.65 | 78 | Palliative (P) | 2022-01-15 | 2022-01-19 | BORTEZOMIB + THALIDOMIDE | 02 | N | TCH | 100701518 |
| 20189860 | 20158071 | 0 | 101.3 | null | 2018-05-11 | 2018-06-01 | CAPECITABINE + IRINOTECAN + Panitumumab | 02 | null | FLUOROURACIL + RT | 100219824 |
| 20189888 | 20158072 | 1.64 | 115.6 | Curative (C) | 2017-12-19 | 2017-12-25 | Capecitabine + Streptozocin | 02 | N | ECF | 100851622 |
| 20189892 | 20158073 | 1.91 | 94 | Curative (C) | null | 2018-06-25 | OSIMERTINIB | 02 | N | CETUXIMAB + FLUOROURACIL | 100827881 |
| 20190292 | 20158074 | 1.75 | 91.5 | null | 2020-04-08 | 2020-04-08 | Azacitidine | 02 | N | ACTICCA-1 TRIAL | 101266166 |
| 20190704 | 20158075 | 1.6 | 72.8 | Palliative (P) | 2018-05-19 | 2019-02-21 | Bortezomib + Daratumumab | 02 | N | ECF | 101768149 |
| 20190786 | 20158076 | 1.82 | 94 | null | 2019-01-09 | 2019-01-10 | CISPLATIN + FLUOROURACIL + Trastuzumab | 02 | null | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 101626160 |
| 20190951 | 20158077 | 1.98 | 61 | null | 2017-10-16 | 2018-03-06 | CAPECITABINE + MITOMYCIN + RT | 02 | N | PERTUZUMAB + TRASTUZUMAB | 101577790 |
| 20191296 | 20158078 | 0 | 117.1 | 03 | 2019-07-28 | 2019-07-28 | Temozolomide + RT | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101505778 |
| 20191467 | 20158079 | 1.56 | 60.5 | 03 | 2019-01-23 | 2019-02-03 | Trastuzumab + VINORELBINE | 02 | N | BRENTUXIMAB | 100543125 |
| 20191722 | 20158080 | 1.75 | 69 | Palliative (P) | 2018-09-27 | 2019-07-12 | Pemetrexed | 02 | N | CETUXIMAB + IRINOTECAN | 100789396 |
| 20191880 | 20158081 | 1.51 | 63.8 | Palliative (P) | 2017-07-19 | 2017-08-29 | FOCUS4 TRIAL | 02 | null | CARBOPLATIN + TEYSUNO | 100512570 |
| 20192236 | 20158082 | null | null | Palliative (P) | 2016-05-29 | 2016-05-29 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | OXALIPLATIN + MDG + PANITUMUMAB | 101713994 |
| 20192517 | 20158083 | 1.53 | 60 | Adjuvant (A) | 2019-05-12 | 2019-06-14 | FLUOROURACIL + RT | 02 | null | BINIMETINIB + ENCORAFENIB | 100811264 |
| 20192598 | 20158084 | 1.82 | 72.4 | Palliative (P) | 2019-11-14 | 2019-11-27 | ECarboX | 02 | N | IPILIMUMAB | 101596904 |
| 20192633 | 20158085 | 1.72 | 53.2 | null | 2018-04-16 | 2018-05-27 | CISPLATIN + FLUOROURACIL + Trastuzumab | N | N | CABAZITAXEL | 100468754 |
| 20192799 | 20158087 | 1.52 | 80.2 | null | 2017-04-29 | 2017-07-26 | CISPLATIN + FLUOROURACIL + RT | 02 | null | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 101216402 |
| 20192828 | 20158088 | 1.71 | 80.2 | Curative (C) | 2016-07-03 | 2016-07-05 | Bortezomib + CYCLOPHOSPHAMIDE | 02 | N | CISPLATIN + RT | 100317739 |
| 20193514 | 20158090 | 1.81 | 67.7 | null | 2019-03-29 | 2019-04-08 | Carboplatin + Cetuximab (>Cycle 2) | 02 | null | EOF | 100967649 |
| 20193552 | 20158091 | 1.6 | 7.7 | Palliative (P) | 2019-09-27 | 2019-10-22 | Cetuximab +Cisplatin + FU (Cycle 1) | 02 | N | CISPLATIN + VINORELBINE | 100636346 |
| 20193638 | 20158092 | 1.85 | 73.9 | Palliative (P) | 2019-08-21 | 2019-11-21 | CAP + RT | 02 | N | THALIDOMIDE | 101825471 |
| 20193764 | 20158093 | 1.71 | 105 | Neo-adjuvant (N) | 2018-07-24 | 2018-08-08 | Rituximab | 02 | N | CISPLATIN + PEMETREXED | 100878145 |
| 20193788 | 20158094 | 1.53 | 65.3 | Palliative (P) | 2018-01-22 | 2019-01-09 | Chlorambucil | 02 | null | GEMCITABINE + OXALIPLATIN | 100021253 |
| 20193816 | 20158095 | 1.57 | 73 | Palliative (P) | 2019-09-07 | 2019-11-01 | Irinotecan + Raltitrexed | N | null | CISPLATIN + CYTARABINE + ETOPOSIDE + RITUXIMAB | 100567206 |
| 20194172 | 20158096 | 1.79 | 74.2 | Palliative (P) | 2017-12-10 | 2017-12-10 | Hydroxycarbamide | 02 | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100352389 |
| 20194533 | 20158098 | 1.61 | 98.4 | null | 2017-08-21 | 2017-09-01 | CHOP R - 21 days | 02 | null | OXALIPLATIN + MDG + PANITUMUMAB | 100062470 |
| 20194727 | 20158099 | 1.83 | 84.4 | 03 | 2017-04-29 | 2017-05-28 | Melphalan IV High dose | 02 | null | EOF | 101849873 |
| 20194746 | 20158100 | 1.71 | 56 | Curative (C) | 2016-03-30 | 2016-08-12 | Capecitabine+Cisplatin+Streptozocin | null | N | BORTEZOMIB + RITUXIMAB | 101348927 |
| 20194882 | 20158101 | 1.65 | 104.3 | null | 2019-10-02 | 2019-12-31 | ECarboX | 02 | N | CAPECITABINE + LOMUSTINE | 100175880 |
| 20195081 | 20158103 | 1.81 | 68.8 | Curative (C) | 2018-12-09 | 2019-02-28 | BALLAD Trial | 02 | N | GEMCITABINE + OXALIPLATIN | 100873840 |
| 20195087 | 20158104 | 1.65 | null | Curative (C) | 2020-05-25 | 2020-05-25 | null | 02 | null | GEMCITABINE + PACLITAXEL | 100076109 |
| 20195211 | 20158105 | 1.77 | 73.2 | null | 2018-12-22 | 2018-12-23 | ARISTOTLE TRIAL | 02 | null | COSMIC TRIAL | 100134615 |
| 20195253 | 20158106 | 1.57 | null | Adjuvant (A) | 2014-12-19 | 2015-02-26 | Bevacizumab + Irinotecan + MdG | 01 | N | BEVACIZUMAB + FLUOROURACIL + OXALIPLATIN | 100199770 |
| 20195460 | 20158107 | 1.66 | 94.55 | Neo-adjuvant (N) | 2019-04-13 | 2019-05-23 | Letrozole + Palbociclib | N | null | PHITT D2 CARBOPLATIN / ETOPOSIDE | 101552716 |
| 20195643 | 20158108 | 1.81 | 182 | null | 2018-05-27 | 2018-05-27 | CETUXIMAB + MDG | 02 | null | CARBOPLATIN + VINORELBINE | 101731291 |
| 20195682 | 20158109 | 1.52 | 64.1 | null | 2018-04-23 | 2018-05-15 | Bevacizumab + CAPECITABINE + OXALIPLATIN | 2 | null | CAPECITABINE + CISPLATIN + MITOMYCIN | 100723794 |
| 20197298 | 20158111 | 1.3 | 61.8 | Neo-adjuvant (N) | 2019-09-13 | 2019-09-13 | CTD | N | N | AML18 TRIAL | 101227674 |
| 20197652 | 20158112 | 1.75 | 67.4 | 03 | 2018-06-11 | 2018-06-16 | Bevacizumab + Irinotecan + MdG | 02 | N | CISPLATIN + DOXORUBICIN | 101151692 |
| 20197694 | 20158113 | 1.82 | 69.3 | Palliative (P) | 2019-11-04 | 2020-04-18 | CETUXIMAB + IRINOTECAN | 02 | N | CYCLOPHOSPHAMIDE + THALIDOMIDE | 100150951 |
| 20197771 | 20158114 | 1.8 | 84.2 | Palliative (P) | 2019-05-21 | 2019-05-21 | null | 02 | N | FLUDARABINE | 101740973 |
| 20198018 | 20158115 | 1.8 | 76.9 | null | 2022-04-03 | 2022-04-07 | Bortezomib + MELPHALAN | 02 | null | GEMCITABINE + TEYSUNO | 100764418 |
| 20198106 | 20158116 | 1.55 | 0 | null | 2018-11-01 | 2018-12-05 | Epirubicin | 01 | null | ARISTOTLE TRIAL | 101499597 |
| 20198126 | 20158117 | 1.65 | 85.1 | Palliative (P) | 2020-11-20 | 2020-12-01 | ECF | 02 | N | ICE | 100341536 |
| 20198192 | 20158118 | 0 | 69.9 | Palliative (P) | 2019-09-28 | 2019-09-29 | Docetaxel+Gemcitabine (no prior RT) | N | null | OSIMERTINIB | 100980667 |
| 20198502 | 20158119 | 1 | null | null | 2018-04-19 | 2018-04-20 | Eribulin | 02 | null | NEO-AEGIS TRIAL | 100826449 |
| 20198916 | 20158120 | 1.65 | 88.2 | Palliative (P) | 2019-02-23 | 2021-08-09 | Bevacizumab + Irinotecan + MdG | Y | null | ARISTOTLE TRIAL | 100498854 |